Pharynx Cancer Completed Phase 0 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0031604 (Pharynx Cancer)Completed0
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00140556Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck CancerTreatment